Assessing the Effectiveness of Sanofi Pasteur's Dengue Vaccine (Dengvaxia) Against Hospitalization and Symptomatic Infection in the State of Parana - Brazil

Dengue Clinical Trial

Official title:

Assessing the Effectiveness of Sanofi Pasteur's Dengue Vaccine (Dengvaxia) Against Hospitalization and Symptomatic Infection in the State of Parana - Brazil

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03960385
• Other study ID #: DNG10042
• Status: Completed
• Start date: August 1, 2017
• Est. completion date: March 1, 2020

Study information

• Verified date: September 2020
• Source: Albert B. Sabin Vaccine Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study seeks to assess the effectiveness of Sanofi Pasteur´s dengue vaccine (Dengvaxia®) according to the age, dose and municipality of residence in five municipalities of Paraná State. Specific objectives include:

• To assess the effectiveness of Dengvaxia® in preventing dengue hospitalization and dengue symptomatic cases.

• To assess the effectiveness of Dengvaxia® in preventing dengue hospitalization and dengue symptomatic cases according in the following age groups 15 to 18 and 19 to 27 years of age in the municipalities of Maringá, Foz de Iguaçu, Londrina, Sarandi and Paranaguá.

• To assess the effectiveness of Dengvaxia® in preventing dengue hospitalization and dengue symptomatic cases in the following age groups 9 to 14 and 28 to 45 years of age in the municipality of Paranaguá.

Description:

The effectiveness of Sanofi Pasteur´s dengue vaccine (Dengvaxia®) according to the age will be assessed in five municipalities of Paraná State - Maringá, Foz de Iguaçu, Londrina, Sarandi and Paranaguá. Any health service located in each of the five municipalities may report a suspected dengue case. However, in all five municipalities, there is a large public emergency service, the UPA. There are currently three UPA in Londrina, two in Maringá and Foz do Iguaҫu and one each in Paranaguá and Sarandi. These facilities are responsible for reporting the majority of suspected dengue cases. In Londrina and Maringá, the private health sector also provides emergency care. The implementation of the study protocol adds a collection of a blood sample for PCR to the existing protocol for addressing suspected dengue cases among individuals within the target vaccination age groups.

The study will count on the activities already carried out by teams of epidemiological surveillance of dengue intensifying the identification of the serotype through the laboratory method RT-PCR (Reverse Transcription Polymerase Chain Reaction) in real time. In addition, the investigators will identify hospitals and health units that attend dengue cases for sample collection, to perform real-time RT-PCR and initial processing of the blood samples collected from the controls.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1854
• Est. completion date: March 1, 2020
• Est. primary completion date: March 1, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 9 Years to 44 Years

Eligibility

Inclusion criteria for cases:

• Individuals living in the municipalities of Sarandi, Paranaguá, Londrina, Maringá or Foz de Iguaçu in the three stages of vaccination

• Individuals with ages ranging from 9 to 44 years for the municipality of Paranaguá and 15 to 27 years for the municipalities of Sarandi, Londrina, Maringá and Foz de Iguaçu

• All participants who are 18 years of age or older sign the informed consent form

• All minors under the age of 18 who sign the consent form and have the consent form signed by a guardian for the minor

• Case with virological isolation of one of the dengue viruses

Case exclusion criteria:

• Those who have been deprived of their liberty (jails, penitentiaries, drug addicts, etc.) within 15 days before the onset of signs and symptoms

Inclusion criteria for controls:

• Individuals without symptoms for dengue in the 15 days prior to the onset of symptoms of the case

• IgM negative for dengue

• Individuals living in the municipalities of Paranaguá, Londrina, Maringá, Sarandi or Foz de Iguaçu in the three stages of vaccination

• Belongs to the same age group as case

• Participants aged between 9 and 44 years for the municipality of Paranaguá

• Participants 15 to 27 years for the municipalities of Maringá, Foz de Iguaçu, Londrina and Sarandi

• Resides in the same neighborhood as the case, study at the same institution as the case or work in the same company as the case for at least 15 days before the onset of the case symptoms

• Participants that are 18 years of age or older and who sign the informed consent form

• All minors under the age of 18 who sign the consent form and have the consent form signed by a guardian for the minor

Related Conditions & MeSH terms

• Dengue

Intervention

Biological:
• CYD-TDV
Dengue vaccine

Locations

Country	Name	City	State
Brazil	Augusto Leopoldo Ayrosa Galvão Study Center	São Paulo

Sponsors (5)

Lead Sponsor	Collaborator
Albert B. Sabin Vaccine Institute	Centro de Estudos Augusto Leopoldo Ayrosa Galvão, Ministry of Health of Brazil, Pan American Health Organization, State of Parana/Health Department of Parana

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dengue symptomatic case	Confirmed (by PCR) case of dengue fever	Aug 2017 - March 2020
Secondary	Dengue hospitalization	Hospitalization for severe dengue fever	Aug 2017 - March 2020